MiNK Therapeutics (NASDAQ:INKT) Rating Lowered to Strong Sell at Wall Street Zen

Key Points

• MiNK Therapeutics (NASDAQ:INKT) has been downgraded to a "strong sell" rating by Wall Street Zen, following similar downgrades from other analysts.
• The company's stock has struggled recently, opening at $14.90, with a consensus rating of "Moderate Buy" and an average price target of $37.50.
• MiNK Therapeutics reported an EPS of ($1.06) for the latest quarter, missing analyst estimates of ($0.55) significantly, and is expected to post -2.75 EPS for the current year.

Wall Street Zen cut shares of MiNK Therapeutics (NASDAQ:INKT - Free Report) to a strong sell rating in a research report sent to investors on Saturday morning.

INKT has been the topic of several other research reports. HC Wainwright upgraded shares of MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price objective on the stock in a report on Friday, August 15th. Zacks Research downgraded shares of MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday, August 18th. B. Riley upgraded shares of MiNK Therapeutics to a "strong-buy" rating in a report on Friday, July 18th. Finally, William Blair downgraded shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $37.50.

MiNK Therapeutics Stock Performance

INKT traded down $0.33 during trading on Friday, hitting $14.57. The stock had a trading volume of 17,341 shares, compared to its average volume of 157,536. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00. The company has a 50 day simple moving average of $14.79 and a 200-day simple moving average of $10.43.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.51). As a group, analysts expect that MiNK Therapeutics will post -2.75 earnings per share for the current year.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.